Monday, November 15, 2010 11:33:54 PM
1300 South Highland Avenue
Clearwater, FL 33756
United States - Map
Phone: 727-447-2998
Website: http://www.procyoncorp.com
Details
Index Membership: N/A
Sector: Healthcare
Industry: Drug Related Products
Full Time Employees: 10
Business Summary
Procyon Corporation, through its subsidiary, Amerx Health Care Corp., develops and markets medical products used in the treatment of pressure ulcers, dermatitis, inflammation, and other skin problems in the United States. The company?s products include the AmeriGel Hydrogel Wound Dressing and Amerigel Hydrogel Saturated Gauze Dressing, which are used as a wound dressing to manage stages I-IV pressure ulcers, stasis ulcers, diabetic skin ulcers, post surgical incisions, cuts, abrasions, first and second degree burns, and skin irritations; and AmeriGel Premium Care Lotion, a therapeutic skin conditioner containing emollients that restore moisture to fragile skin and alleviate problematic skin conditions. Its products also comprise the AmeriGel Barrier Lotion provides barrier protection to shield the skin from excess moisture and reduce harmful effects to the skin from friction and chafing; AmeriGel Saline Wound Wash, a non-sterile saline solution containing Oakin and used for wound cleansing; and the Amerigel Post Op Surgical Kit. Procyon Corporation sells its products through distributors to healthcare institutions, such as physicians, nursing homes, and home healthcare agencies; and to retailers, including national and regional chain stores, and pharmacies. The company was incorporated in 1987 and is based in Clearwater, Florida.
Recent PCYN News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/22/2024 10:17:52 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 02/13/2024 10:26:50 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/04/2024 09:12:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/22/2023 07:16:27 PM
- Form DEFR14A - Revised definitive proxy soliciting materials • Edgar (US Regulatory) • 10/25/2023 06:54:13 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/12/2023 07:44:26 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 08:24:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2023 09:24:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2023 08:27:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2023 08:26:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2023 08:26:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2023 06:57:58 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM